Amgen, Cytokinetics to Continue Phase 3 Heart Failure Trial
February 26 2020 - 10:04AM
Dow Jones News
By Michael Dabaie
Amgen Inc., Cytokinetics Inc. and Servier said they would
continue the GALACTIC-HF Phase 3 heart failure trial following a
planned interim analysis.
The companies said the Data Monitoring Committee recommended the
Phase 3 clinical trial of omecamtiv mecarbil in patients with heart
failure continue without changes.
Topline results are expected in the fourth quarter of 2020.
GALACTIC-HF completed enrollment of more than 8,200 patients in
35 countries who were either hospitalized at the time of enrollment
for a primary reason of heart failure, or had a hospitalization or
admission to an emergency room for heart failure within one year
prior to screening.
Omecamtiv mecarbil is being developed by Amgen in collaboration
with Cytokinetics, with funding and strategic support from
Servier.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
February 26, 2020 09:49 ET (14:49 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Apr 2023 to Apr 2024